{"filing":{"accession_number":"0001193125-26-389264","cik":"0000818686","ticker":"TEVJF","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","form":"8-K","filing_date":"2026-09-11","report_date":"2026-09-09","primary_document":"d81245d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/818686/000119312526389264/d81245d8k.htm"},"events":[{"id":32926,"run_id":30271,"accession_number":"0001193125-26-389264","anchor_item_number":"8.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Teva Pharmaceutical announced the successful pricing and entry into an underwriting agreement for approximately $4.9 billion in senior notes across multiple tranches (€1.5 billion in Euro Notes maturing 2032–2037 and $3.2 billion in USD Notes), with proceeds intended for redemption of existing debt and general corporate purposes.","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVJF","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36219,"accession_number":"0001193125-26-389264","item_number":"7.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Teva announced the successful pricing of approximately $4.9 billion in senior notes across multiple tranches (EUR and USD denominated notes maturing 2032–2037). The company intends to use net proceeds to redeem existing debt and for general corporate purposes. This is a material creation of new direct financial obligations disclosed via press release under Item 7.01 (Regulation FD Disclosure), fitting the debt_issuance category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:07:16.431821+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36220,"accession_number":"0001193125-26-389264","item_number":"8.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Teva Pharmaceutical entered into an underwriting agreement on September 9, 2026, to issue approximately $4.9 billion (equivalent) in senior notes across multiple tranches (€1.5 billion in Euro Notes and $3.2 billion in USD Notes) with maturities ranging from 2032 to 2037. This represents a material creation of direct financial obligations by the company and its subsidiary issuers, with the sale expected to close on September 16, 2026. The company explicitly stated it will use proceeds to redeem existing notes and for general corporate purposes including debt repayment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:07:16.431821+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36219,"accession_number":"0001193125-26-389264","item_number":"7.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Teva announced the successful pricing of approximately $4.9 billion in senior notes across multiple tranches (EUR and USD denominated notes maturing 2032–2037). The company intends to use net proceeds to redeem existing debt and for general corporate purposes. This is a material creation of new direct financial obligations disclosed via press release under Item 7.01 (Regulation FD Disclosure), fitting the debt_issuance category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:07:16.431821+00:00","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVJF","filing_date":"2026-09-11"},{"id":36220,"accession_number":"0001193125-26-389264","item_number":"8.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Teva Pharmaceutical entered into an underwriting agreement on September 9, 2026, to issue approximately $4.9 billion (equivalent) in senior notes across multiple tranches (€1.5 billion in Euro Notes and $3.2 billion in USD Notes) with maturities ranging from 2032 to 2037. This represents a material creation of direct financial obligations by the company and its subsidiary issuers, with the sale expected to close on September 16, 2026. The company explicitly stated it will use proceeds to redeem existing notes and for general corporate purposes including debt repayment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:07:16.431821+00:00","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVJF","filing_date":"2026-09-11"}]}